ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

Transmembrane signalling systems are an integrated series of pathways, leading to various effects depending on cell type. A simplified picture is of a ligand activating a cell surface receptor, initiating a series of events inside the cell which, in turn, leads to gene expression. The real story is rather more complex and researchers investigating different areas of signal transduction gathered together to discuss and present topics of potential therapeutic relevance at the recent IBC UK conference on Signal Transduction - Targets for Therapeutic Intervention [London, UK; November 1997]. Although based at a fundamental biological research level, the conference did raise issues which will need to be addressed by any pharmaceutical company wishing to develop a drug targeting this area.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

摘要:

A new formulation of interferon-&bgr;-1a has shown great promise as a treatment for remitting-relapsing multiple sclerosis (MS) in a phase III trial involving 560 patients. This is the largest trial ever conducted to investigate a treatment for this condition. The new formulation, which is manufactured by Ares-Serono, is now awaiting approval from European regulatory authorities. Speaking toInpharma, Professor Lance Blumhardt from Queen's Medical Centre, Nottingham, UK, who was one of the lead investigators in the trial, said that the he believes that the drug offers certain advantages over currently available treatments.

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1997

数据来源: ADIS